'The cost will drop'. Myriad Genetics' shares drop as competitors enter
'The cost will drop'. Myriad Genetics' shares drop as competitors enter
About this item
Full title
Author / Creator
Publisher
United States: Crain Communications, Inc
Journal title
Language
English
Publication information
Publisher
United States: Crain Communications, Inc
Subjects
More information
Scope and Contents
Contents
Hours after the U.S. Supreme Court invalidated Myriad Genetics' monopoly on testing for two breast cancer genes, the company's stock went tumbling as competitors announced plans to offer the same services at lower prices. Similar genetic testing for the genes was announced by laboratory giant Quest Diagnostics, while GeneDx announced it would start...
Alternative Titles
Full title
'The cost will drop'. Myriad Genetics' shares drop as competitors enter
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_reports_1369848369
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_reports_1369848369
Other Identifiers
ISSN
0160-7480
E-ISSN
1944-7647
